Business Context and Reporting Period
Company: MyMD Pharmaceuticals, Inc. (MYMD)
Filing Type: Form 8-K (Current Report)
Date of Report: February 21, 2023
Reporting Period: Event date February 21, 2023; Signed February 23, 2023
Business Context: The company is incorporated in New Jersey and trades on The Nasdaq Capital Market. This filing reports the entry into a material definitive agreement regarding a registered direct offering.
Key Financial Metrics
This filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The filing focuses exclusively on a capital raising transaction.
| Transaction Component | Details |
|---|---|
| Securities Sold | 15,000 shares of Series F Convertible Preferred Stock |
| Stated Value | $1,000 per share |
| Warrants Issued | Warrants to acquire up to 6,651,885 shares of Common Stock |
| Investor Type | Certain accredited investors |
Material Changes
The material change reported is the execution of a Securities Purchase Agreement on February 21, 2023. This agreement facilitates the sale of new equity securities (Series F Convertible Preferred Stock) and warrants to accredited investors. No comparative financial data or changes in operating metrics versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the completion of the definitive agreement for the registered direct offering. Legal opinions regarding the legality of the issuance were provided by DLA Piper LLP (US) and Haynes and Boone, LLP.
Guidance and Outlook: The filing text does not provide forward-looking guidance, revenue projections, or strategic outlook beyond the immediate capital raise.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this 8-K, other than the standard implications of issuing convertible preferred stock and warrants subject to adjustment.
Investor Verification Checklist
- Verify the total gross proceeds raised from the sale of the 15,000 Series F shares and associated warrants (not explicitly stated in this text).
- Review the specific conversion terms and adjustment mechanisms for the Series F Convertible Preferred Stock.
- Examine the exercise price and expiration terms for the 6,651,885 warrants issued.
- Check for any dilution impact on existing common shareholders resulting from the conversion of preferred stock and exercise of warrants.
- Confirm the use of proceeds as disclosed in the full Securities Purchase Agreement or related press releases.